// App-Quantinova.ai

: Blood eosinophil (EOS) count, exacerbation rate and response to roflumilast in patients with severe COPD

Researchers

Presenter

  • Fernando J. Martinez

Principal Investigators

  • Klaus Rabe

  • Peter Calverley

  • Leonardo Fabbri

  • Sanjay Sethi

  • Emilio Pizzichini

  • Andrew McIvor

  • Antonio Anzueto

  • Vijay Alagappan

  • Shahid Siddiqui

  • Colin Reisner

  • Debasree Purkayastha

  • Jonas Roman

  • Stephen Rennard

Medical Centers

  • Weill Cornell Medical College - New York - United States of America

  • LungenClinic, Grosshansdorf, Germany

  • MRC/ARUK Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom

  • Univeristy of Modena and Reggio Emilia, Modena, Italy

  • University at Buffalo, State University of New York, Buffalo, United States of America

  • Universidade Federal de Santa Maria, Santa Maria, Brazil

  • McMaster University, Firestone Institute of Respiratory Health, St. Joseph’s Healthcare, Hamilton, Canada

  • University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

  • AstraZeneca Gaithersburg, Gaithersburg, United States of America

  • Astra Zeneca, Manchester, United Kingdom

  • AstraZeneca, Gothenburg, Sweden

  • University of Nebraska Medical Center, Omaha, NE, United States

Locations

  • United States

  • Germany

  • United Kingdom

  • Italy

  • Brazil

  • Canada

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • roflumilast

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved